GlassScriptPhysician profile
Kellie Loughran
NPI 1497228159
$954.84
in general payments reported to CMS, 2019-2025
15 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $191 · 2023: $181 · 2024: $120 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $321.08 | 2021-2025 | |
| Gilead Sciences, INC. | $151.19 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.81 | 2022 | |
| Inspire Medical Systems, INC. | $66.31 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $64.03 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $55.44 | 2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $54.66 | 2025 | Veozah |
| Medtronic, INC. | $25.88 | 2024 | Intellis Adaptivestim |
| Novo Nordisk INC | $22.89 | 2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $20.89 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $19.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.80 | 2024 | Xifaxan |
| Seqirus USA INC | $16.52 | 2025 | Fluad, Flucelvax |
| Amphastar Pharmaceuticals, INC. | $14.82 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Loughran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.